Roush GC, et al. -Previous studies have ignored differences among thiazide-type diuretics, while favoring renin–angiotensin system inhibitors (RASIs) over other antihypertensives for reducing left ventricular mass (LVM). Researchers tested the hypothesis, based on evidence regarding potency, cardiovascular events, and electrolytes, that “CHIP” diuretics (CHlorthalidone, Indapamide and Potassium-sparing Diuretic/hydrochlorothiazide) could equal RASIs for reducing LVM. Analysis of data from 12 relevant double-blind randomized trials revealed that CHIPs surpassed RASIs for attenuating LVM and end-diastolic LV internal dimension in patients with hypertension. Relative to RASIs, CHIPs reduction in LVM was 37% greater. Moreover, with trial duration, CHIPs superiority tended to increase.